Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-08-09
1996-10-01
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514260, 514 19, 544284, 544285, 544287, C07D23995, C07D23996, A61K 31505, A61K 3144
Patent
active
055611338
DESCRIPTION:
BRIEF SUMMARY
This is a national stage application, filed under 35 U.S.C. .sctn.371, of PCT/GB93/00540, filed Mar. 16, 1993, published as WO93/19051 Sep. 30, 1993.
This invention relates to novel anti-cancer agents and more particularly it relates to quinazoline derivatives which possess anti-cancer activity.
One group of anti-cancer agents comprises antimetabolites having anti-folate activity, such as aminopterin and methotrexate. A newer compound of this type which showed considerable promise in clinical trials is known as CB3717 and is described and claimed in United Kingdom Patent No. 2 065 653B. Despite its promising activity against human breast,ovarian and liver cancer, however, CB3717 shows symptoms of toxicity in humans, particularly in relation to the liver and kidneys. Such adverse side effects are reduced in compounds in which the 2-amino substituent of CB3717 is either missing or is replaced by one of various alternative substituents as described and claimed respectively in United Kingdom Patents Nos. 2 175 903 and 2 188 319.
Compounds of this type are believed to act as anti-cancer agents by inhibiting the enzyme thymidylate synthase which catalyses the methylation of deoxyuridine monophosphate to produce thymidine monophosphate which is required for DNA synthesis. The anti-cancer activity of CB3717 and like compounds may be assessed in vitro by determining their inhibitory effect on that enzyme, and in cell cultures by their inhibitory effect on cancer cell lines such as the mouse lymphoma cell line L1210 and the human breast cancer cell line MCF-7.
Antimetabolites such as aminopterin and methotrexate which are inhibitors of enzymes which utilise folic acid derivatives have also shown promise in the treatment of various allergic diseases such as allergic rhinitis, atopic dermatitis and psoriasis.
We have now found that certain quinazoline derivatives not only show a good level of activity, in particular in respect of their ability to inhibit thymidylate synthase, but also have a different mode of action from CB3717 and other related quinazoline derivatives which have been described. Thus it is believed that CB3717 and more particularly its 2-methyl analogue, which is described and claimed in UK Patent No. 2 188 319, owe anti-tumour activity to an intracellular polyglutamate form but that the compounds of the present invention act directly without undergoing a significant degree of gamma-glutamylation. This alternative mode of action of the compounds of the present invention provides the potential for more precise control in the administration of the compounds to cancer patients, deriving especially from a shorter period of intracellular retention following the completion of administration and a lack of dependence on polyglutamylation which may vary in degree from one patient to another. Moreover, the replacement of the L-glutamic acid residue of CB3717 by an alternative group in the compounds of the present invention will confer different physical properties thereby influencing the overall characteristics of the compounds.
Accordingly the present invention comprises a quinazoline of formula (I): ##STR3## wherein R.sup.1 is hydrogen or amino;
or R.sup.1 is alkyl, alkoxy or alkylthio each of up to 6 carbon atoms;
or R.sup.1 is aryl or aryloxy, each of up to 10 carbon atoms;
or R.sup.1 is halogeno, hydroxy or mercapto; substituents selected from halogeno, hydroxy and alkanoylamino each of up to 6 carbon atoms; substituents selected from hydroxy and alkoxy of up to 6 carbon atoms; alkoxyalkyl, mercaptoalkyl, alkylthioalkyl, halogenoalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkanoylalkyl, carboxyalkyl, carbamoylalkyl or alkanoyl each of up to 6 carbon atoms; bears one or more substituents selected from halogeno, cyano, nitro, hydroxy, amino and carbamoyl and alkyl, alkoxy, halogenoalkyl, alkanoylamino and alkoxycarbonyl each of up to 6 carbon atoms; N-terminal amino acid residue thereof attached to the carbonyl group of COR.sup.3 is an amino acid residue ##STR4## in which A is a carbon
REFERENCES:
patent: 4447608 (1984-05-01), Jones et al.
patent: 4564616 (1986-01-01), Jones et al.
patent: 4746659 (1988-05-01), DeGraw et al.
patent: 4767761 (1988-08-01), Rosowsky
patent: 4981856 (1991-01-01), Hughes
patent: 4985441 (1991-01-01), Hughes et al.
patent: 4992550 (1991-02-01), Hughes
patent: 4996207 (1991-02-01), Nair et al.
patent: 5081124 (1992-01-01), Hughes
patent: 5089499 (1992-02-01), Barker et al.
patent: 5112837 (1992-05-01), Burrows et al.
patent: 5187167 (1993-02-01), Hughes
patent: 5236927 (1993-08-01), Jones et al.
patent: 5252573 (1993-10-01), Barker et al.
patent: 5280027 (1994-01-01), Andrew et al.
E. Sikora et al. "Formation and Retention. . . " Biochem. Pharmacol. vol. 37 No. 21, (1988), pp. 4047-4054.
W. Thomas Mueller et al. "Inhibition of chicken liver. . ." Biochem. Pharmacol. vol. 37 No. 3, (1988), pp. 449-451.
Ka-yun Ng et al. "Liposome-dependent delivery. . ." Biochimica et Biophyisica Acta 981 (1989), pp. 261-268.
K, Pawalczak et al. "Quanazoline antifolates inhibiting. . . " J. Med. Chem. 1989, 32, pp. 160-165.
U. Kuefner et al. "Occurreance and significance of diastereomers. . ." Biochemistry 1990, 29, pp. 10540-10545.
G. M. F. Bisset et al. "Syntheses and thymidylate synthase. . ." Reprinted from Jour of Medicinal Chemistry, 1992, 35, pp. 859-866.
J, Galivan et al. ".UPSILON.-fluoromethotrexate: Synthesis. . ." Proc. Natl. Acad. Sci. USA vol. 82 (May 1985), pp. 2598-2602.
J. J. McGuire et al. "Biochemical & Growth inhibitory. . ." Cancer Research 49 (Aug. 15, 1989), pp. 4517-4525.
J. K. Coward et al. "Fluoroglutamate-Containing folates. . ." Chemistry and Biology of Pteridines 1989, pp. 1200-1202.
T. C. Stephens et al. "Use of murine L5178Y" Chem. & Biol. of Pteridines & Folates, New York, 1993, pp. 589-592.
A. H. Calvert et al. "A phase I evaluation. . ." Jour. of Clinical Oncol. vol. 4 No. 8 (Aug. 1986), pp. 1245-1252.
B. M. J. Cantwell et al. "Phase II study of a novel antifolate. . ." Cancer Treatment Reports vol. 70 No. 11, Nov. 1986, pp. 1335-1336.
M. F. Bassendine et al. "Induction of remission. . ." Jour. of Hepatology, 1987, 4, pp. 349-356.
B. M. J. Cantwell et al. "Phase II study of the antifolate. . ." Euro. Jour. of Cancer Clin. Oncol., vol. 24 No. 4, 1988, pp. 733-736.
C. Sessa et al. "Phase I study of the antifolate. . ." Euro. Jour. of Cancer Clin. Oncol. vol. 24 No. 4, 1988, pp. 769-775.
Jackman et al., "Activity of the Thymidylate Synthase Inhibitor 2-Desamino-N.sup.10 -propargyl-5,8-dideazafolic acid. . .", Cancer Reserach 50, 5212-5218(1990).
Jodrell et al., "The in vivo Metabolic Stability of Dipeptide Analogues. . .", Biochem. Pharmacol., 46, 2229-2234 (1993).
Jackman et al., "The Biochemical Pharmacology of the thymidylate synthase inhibitor. . .", Biochem, Pharmacol., 42, 1885-1895 (1991).
Bavetsias Vassilios
Bisset Graham M. F.
British Technology Group Limited
Grumbling Matthew V.
Shah Mukund J.
LandOfFree
Thymidylate synthase inhibiting quinazolinones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thymidylate synthase inhibiting quinazolinones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thymidylate synthase inhibiting quinazolinones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1502121